<DOC>
	<DOC>NCT00568555</DOC>
	<brief_summary>Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.</brief_summary>
	<brief_title>Effects of Low Dose Naltrexone in Fibromyalgia</brief_title>
	<detailed_description>This study will be a placebo-controlled, double-blind, cross-over drug tria. Patients with Primary Fibromyalgia or Gulf War Syndrome will be recruited from the Stanford University Pain Management Center and the surrounding community. Participation in the study will cover 22 weeks. Participants will attend a laboratory session 12 times for progress checkups, and will complete daily measures of symptoms.</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Persian Gulf Syndrome</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome Age 1865. Not taking any opioid analgesic Not pregnant or planning to become pregnant. Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>